"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Descriptor ID |
D009101
|
MeSH Number(s) |
C04.557.595.500 C14.907.454.460 C15.378.147.780.650 C15.378.463.515.460 C20.683.515.845 C20.683.780.650
|
Concept/Terms |
Multiple Myeloma- Multiple Myeloma
- Multiple Myelomas
- Myelomas, Multiple
- Myeloma, Multiple
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Myelomatosis
- Myelomatoses
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma-Multiple
- Myeloma Multiple
- Myeloma-Multiples
|
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 7 | 0 | 7 |
1995 | 8 | 2 | 10 |
1996 | 2 | 0 | 2 |
1997 | 5 | 2 | 7 |
1998 | 6 | 1 | 7 |
1999 | 2 | 2 | 4 |
2000 | 1 | 0 | 1 |
2001 | 6 | 1 | 7 |
2002 | 16 | 5 | 21 |
2003 | 35 | 6 | 41 |
2004 | 22 | 6 | 28 |
2005 | 28 | 2 | 30 |
2006 | 26 | 4 | 30 |
2007 | 39 | 4 | 43 |
2008 | 24 | 7 | 31 |
2009 | 28 | 3 | 31 |
2010 | 23 | 5 | 28 |
2011 | 46 | 4 | 50 |
2012 | 36 | 4 | 40 |
2013 | 52 | 6 | 58 |
2014 | 38 | 1 | 39 |
2015 | 40 | 3 | 43 |
2016 | 41 | 2 | 43 |
2017 | 48 | 4 | 52 |
2018 | 37 | 1 | 38 |
2019 | 39 | 3 | 42 |
2020 | 52 | 1 | 53 |
2021 | 29 | 3 | 32 |
2022 | 34 | 0 | 34 |
2023 | 38 | 0 | 38 |
2024 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis. J Exp Clin Cancer Res. 2024 Mar 05; 43(1):68.
-
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma. Nat Commun. 2024 Feb 08; 15(1):1203.
-
Whole-body MRI in oncology: A comprehensive review. Clin Imaging. 2024 Apr; 108:110099.
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Adv. 2024 01 23; 8(2):388-398.
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.
-
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024 01 10; 14(1):4.
-
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2024 May 01; 130(9):1663-1672.
-
Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts. Am J Hematol. 2024 Feb; 99(2):245-253.
-
Personalized Medicine's Coming of Age: One Drug, One Patient. Clin Cancer Res. 2023 12 01; 29(23):4703-4705.
-
More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023 10 24; 7(20):6275-6284.